News

Acclinate Collaborates with Merck to Increase Clinical Trial Diversity

Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to help increase participation by members of the Black/African American community in Merck’s oncology clinical studies.

“We’re proud to be working with Merck because being a champion for health equity through inclusive research takes strategic orientation and proactiveness. We look forward to seeing how our continued collaboration can positively impact patients,” said Del Smith, CEO and Co-Founder of Acclinate.

As part of the initiative, Acclinate will utilize its NOWINCLUDED platform, a trusted health education and engagement source created by and for the Black/African American community. NOWINCLUDED offers access to health information and resources around disorders that disproportionately affect communities of color and provides a space for community members to share their experiences and connect. With a wealth of original and curated content, NOWINCLUDED is designed to build trust between healthcare providers and people from historically marginalized racial and ethnic groups to empower them to make better-informed health decisions, including considering clinical trial participation.

Additionally, Acclinate will contribute its proprietary predictive analytics tool, e-DICT (Enhanced Diversity in Clinical Trials), that provides real-time reporting on community access and engagement activities and insights into potential participants. It also offers key features such as displaying access potential, tracking engagement and mobilization progress and is driven by a patent-pending Participation Probability Index (PPI) that assesses the likelihood of community members participating in clinical research.

“Community engagement is a key step toward increasing diversity in clinical trials,” said Adrelia Allen, Executive Director, Clinical Trial Patient Diversity, Merck. “We’re excited to collaborate with Acclinate to raise awareness among the Black/African American community of available clinical trials for people with cancer. It is important that our research appropriately reflects the communities we serve.”

 

Learn more here.

Recent News

04/02/2025

VCU startup wins $800k grant to propel its infection-fighting surgical gel

With an innovation that could advance brain and spinal surgeries, a Virginia Commonwealth University startup has received an $800,000 state grant to support development of its infection-fighting gel. Pascal Medical Corp. is one of four grant recipients to receive awards from Virginia Catalyst, a nonprofit created by the General Assembly and funded by the state’s general

04/02/2025

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. After 6 weeks of continued whole body application

04/02/2025

Charlottesville Angel Network Celebrates 10 Years, Surpasses $20 Million in Investments

The Charlottesville Angel Network (CAN), a group of accredited investors dedicated to supporting early-stage ventures, proudly marks its 10th anniversary this month. Since its inception, CAN angel investor members have invested more than $20 million in nearly 80 startups, fostering innovation both locally and beyond. Reflecting on a decade of achievements, CAN has realized returns